Thus, we believe that 50% inhibition of binding of APS-IgG to β2GPI that we have demonstrated with PEG-DI is of potential clinical benefit, because the subpopulation of anti-β2GPI being inhibited is also the group with the major thrombogenic effect. This evidence concerns the gene APOH and autoimmune polyendocrinopathy.